

LIST OF FIGURES.

Figure no.	Title	Page no.
2.1	MRI image of grade III astrocytoma.	16
2.2	Chemical structure of lenalidomide.	20
2.3	Structure of mitochondria.	25
2.4	Warburg effect.	26
2.5	Linear and branched forms of PEI.	27
3.1	UV spectrum of lenalidomide in Methanol: Acetonitrile.	41
3.2	Calibration curve of lenalidomide in Methanol:Acetonitrile.	42
3.3	Interference study.	44
3.4	Spectrum of lenalidomide in methanolic PBS pH 7.4.	45
3.5	Calibration curve of lenalidomide in methanolic PBS pH 7.4.	46
3.6	Reaction of florescamine with primary amine.	47
3.7	Spectra of lenalidomide in brain homogenate and plasma.	49
3.8	Calibration curves for bio analytical method.	50
4.1	Co-precipitation synthesis process.	53
4.2	Synthesis by borohydride reduction.	54
4.3	Solvothermal process assembly and phase transfer procedure.	56
4.4	Assembly for polyol process.	57
4.5	(a) Washing of crude product obtained from polyol process and (b) purified dried product of metallic nanoparticles from polyol process.	57
4.6	Schematic diagram of modification of PEI.	59
4.7	Schematic diagram of fabricated theranostic nanoparticles.	61
4.8	Reaction for co-precipitation synthesis.	62
4.9	Reaction mechanism of tannin acid in synthesis of metal nanoparticles.	62
4.10	DSC thermograms of (a) Iron acetyl acetate and (b) gadolinium acetyl acetate hydrate.	63
4.11	Particle size obtained in solvothermal method with oleyl amine as surfactant.	65
4.12	Particle size analysis of nanoparticles synthesized by polyol method.	66
4.13	Infrared spectra of (a) PEI (b) PEI-FA (c) PEI-TPP and (d) PEI-FA-TPP.	68
4.14	Florescamine assay for determination degree of modification of PEI.	69
5.1	(a) Casting of gelatin blocks as MRI phantoms, (b) Impregnation of metallic nanoparticles in gelatin blocks and (c) Gelatin blocks with controls and samples.	75
5.2	(a) TEM analysis of metallic core (b) high resolution image of metallic core.	78

5.3	MRI images in T1 (light) mode (a) blank gelatin phantom (b) gadolinium oxide nanoparticles (c) Gd doped iron oxide nanoparticles and T2 (dark) mode (d) blank gelatin phantom (e) Iron oxide nanoparticles and (f) Gd doped iron oxide nanoparticles.	80
5.4	EDAX analysis spectrum of metallic nanoparticles.	81
5.5	XRD diffractograms of iron oxide, gadolinium doped iron oxide and gadolinium oxide nanoparticles.	82
5.6	Hysteresis loops of metallic nanoparticles at room temperature.	84
5.7	Temperature curves for metallic nanoparticles exposed to alternating magnetic field.	85
5.8	Thermograms of (a) Drug, (b) PLGA, (c) PVA, (d) Gd doped iron oxide, (e) physical mixture, (f) PEI-FA-TP and (g) Theranostic nanoparticles.	86
5.9	TEM analysis of theranostic nanoparticles.	87
5.10	:Gas chromatograms of standard and theranostic nanoparticles for acetone detection as residual solvent.	88
5.11	Comparison of matrix and core shell type of systems.	89
5.12	(a) TEM image showing polymeric coat thickness over theranostic nanoparticles. (b) Comparison of In vitro drug release profile of drug suspension, drug coated core and theranostic nanoparticles.	91
5.13	Results of stability study at room temperature and refrigerated conditions.	92
6.1	U87MG glioblastoma cell lines cultured aseptically.	98
6.2	Principle of MTT assay.	101
6.3	Results of MTT assay.	102
6.4	Observations of scratch assay at initial phase and after 48 hours.	103
6.5	Confocal image of U87MG cell lines with nucleus (blue), mitochondria (red) and FITC tagged theranostic nanoparticles (green) and their overlay.	105
6.6	3-D visualization of confocal microscopy of U87MG cell lines with mitochondrial internalization of theranostic nanoparticles.	105
6.7	Results of mitochondrial membrane potential assay.	107
6.8	Results of ATP level assay.	107
6.9	Results of PI staining.	108
6.10	Histological observations of mucosal toxicity study.	109
6.11	RBC morphology after treatment with positive control, negative control and formulation of theranostic nanoparticles.	110
6.12	Results of haemolytic toxicity study for formulation	110
7.1	Estimation of drug in brain and plasma of samples from bio distribution study.	117
7.2	Comparison of brain/blood ratio for all time points.	117